Basic Information
| LncRNA/CircRNA Name | SNHG3 |
| Synonyms | NA |
| Region | GRCh38_1:28505980-28510892 |
| Ensemble | ENSG00000242125 |
| Refseq | NR_002909.1 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | papillary thyroid cancer |
| ICD-0-3 | NA |
| Methods | qRT-PCR, Western blot, RIP |
| Sample | PTC tissues,cell lines |
| Expression Pattern | up-regulated |
| Function Description | SNHG3 could bind to miR-214-3p as a competing endogenous RNA (ceRNA) for this miRNA, thereby regulating proteasome 26S subunit non-ATPase 10 (PSMD10) expression, a miR-214-3p target.SNHG3 is an oncogenic lncRNA in PTC, acting at least in part via the miR-214-3p/PSMD10 axis. |
| Pubmed ID | 32048306 |
| Year | 2020 |
| Title | The lncRNA SNHG3 accelerates papillary thyroid carcinoma progression via the miR-214-3p/PSMD10 axis |
External Links
| Links for SNHG3 | GenBank HGNC NONCODE |
| Links for papillary thyroid cancer | OMIM COSMIC |